Nektar Therapeutics (NASDAQ:NKTR) traded up 7% on Thursday . The company traded as high as $108.50 and last traded at $108.44. 2,086,830 shares were traded during trading, a decline of 25% from the average session volume of 2,766,009 shares. The stock had previously closed at $101.30.
Several research analysts have commented on NKTR shares. Cowen restated a “buy” rating and issued a $101.00 target price on shares of Nektar Therapeutics in a research report on Friday, March 2nd. Jefferies Group upped their target price on shares of Nektar Therapeutics to $103.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Canaccord Genuity upped their target price on shares of Nektar Therapeutics to $94.00 and gave the stock a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, Mizuho restated a “buy” rating and issued a $89.00 target price on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $52.62.
The company has a quick ratio of 5.63, a current ratio of 5.82 and a debt-to-equity ratio of 2.79. The company has a market cap of $17,420.00, a PE ratio of -169.28 and a beta of 1.96.
In other news, COO John Nicholson sold 220,144 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $99.27, for a total value of $21,853,694.88. Following the completion of the sale, the chief operating officer now directly owns 267,657 shares of the company’s stock, valued at approximately $26,570,310.39. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher A. Kuebler sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the sale, the director now directly owns 70,500 shares of the company’s stock, valued at $4,135,530. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 482,925 shares of company stock valued at $40,642,596. Company insiders own 6.10% of the company’s stock.
Several large investors have recently modified their holdings of NKTR. Janus Henderson Group PLC lifted its stake in Nektar Therapeutics by 87.8% during the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock valued at $79,903,000 after purchasing an additional 1,556,352 shares during the last quarter. Eagle Asset Management Inc. acquired a new stake in Nektar Therapeutics during the fourth quarter valued at approximately $61,577,000. Rubric Capital Management LP acquired a new stake in Nektar Therapeutics during the third quarter valued at approximately $23,924,000. Carillon Tower Advisers Inc. acquired a new stake in Nektar Therapeutics during the fourth quarter valued at approximately $43,024,000. Finally, BlackRock Inc. lifted its stake in Nektar Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 21,431,388 shares of the biopharmaceutical company’s stock valued at $1,279,883,000 after purchasing an additional 431,269 shares during the last quarter. 94.96% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3254025/nektar-therapeutics-nktr-trading-7-higher.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.